Open AccessChildren's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
Author(s) -
Jeff M. Michalski,
Anna J. Janss,
L. Gilbert Vezina,
Kyle Smith,
Catherine A. Billups,
Peter C. Burger,
Leanne Embry,
Patricia Cullen,
Kristina K. Hardy,
Scott L. Pomeroy,
Johnnie K. Bass,
Stephanie M. Perkins,
Thomas E. Merchant,
Paul Colte,
Thomas J. Fitzgerald,
Timothy N. Booth,
Joel M. Cherlow,
Karin M. Muraszko,
Jennifer Hadley,
Rahul Kumar,
Yuanyuan Han,
Nancy J. Tarbell,
Maryam Fouladi,
Ian F. Pollack,
Roger J. Packer,
Yimei Li,
Amar Gajjar,
Paul A. Northcott
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.02730
Subject(s) - medicine , hazard ratio , medulloblastoma , radiation therapy , oncology , confidence interval , pathology
Children with average-risk medulloblastoma (MB) experience survival rates of ≥ 80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects include deintensification of craniospinal irradiation (CSI) dose and volume.